Compare SLNH & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLNH | OGEN |
|---|---|---|
| Founded | 1961 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.8M | 3.6M |
| IPO Year | N/A | N/A |
| Metric | SLNH | OGEN |
|---|---|---|
| Price | $1.29 | $0.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 5.5M | 93.8K |
| Earning Date | 11-17-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,782,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $0.82 |
| 52 Week High | $5.14 | $18.90 |
| Indicator | SLNH | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.73 | 32.48 |
| Support Level | $1.78 | $0.85 |
| Resistance Level | $2.29 | $0.99 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 1.99 | 0.10 |
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.